nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—testicular cancer	0.234	0.393	CbGbCtD
Bortezomib—SLC31A1—Cisplatin—testicular cancer	0.2	0.336	CbGbCtD
Bortezomib—PTGS1—Ifosfamide—testicular cancer	0.0359	0.0604	CbGbCtD
Bortezomib—CYP2C8—Ifosfamide—testicular cancer	0.0207	0.0349	CbGbCtD
Bortezomib—CYP2C19—Ifosfamide—testicular cancer	0.0174	0.0293	CbGbCtD
Bortezomib—PTGS1—Etoposide—testicular cancer	0.0172	0.0289	CbGbCtD
Bortezomib—CYP2C9—Ifosfamide—testicular cancer	0.0145	0.0243	CbGbCtD
Bortezomib—CYP2C8—Etoposide—testicular cancer	0.0099	0.0167	CbGbCtD
Bortezomib—CYP3A4—Ifosfamide—testicular cancer	0.00841	0.0141	CbGbCtD
Bortezomib—CYP1A2—Etoposide—testicular cancer	0.00767	0.0129	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—testicular cancer	0.00703	0.0118	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—testicular cancer	0.00701	0.0118	CbGbCtD
Bortezomib—CYP3A4—Vinblastine—testicular cancer	0.00446	0.0075	CbGbCtD
Bortezomib—PSMA1—embryo—testicular cancer	0.00438	0.0505	CbGeAlD
Bortezomib—CYP2D6—Doxorubicin—testicular cancer	0.00431	0.00725	CbGbCtD
Bortezomib—CTSG—seminal vesicle—testicular cancer	0.00429	0.0494	CbGeAlD
Bortezomib—CYP3A4—Etoposide—testicular cancer	0.00402	0.00676	CbGbCtD
Bortezomib—PSMD1—seminal vesicle—testicular cancer	0.00346	0.0398	CbGeAlD
Bortezomib—PSMD2—embryo—testicular cancer	0.00326	0.0376	CbGeAlD
Bortezomib—PSMD2—seminal vesicle—testicular cancer	0.00306	0.0353	CbGeAlD
Bortezomib—PSMB8—seminal vesicle—testicular cancer	0.00304	0.0351	CbGeAlD
Bortezomib—PSMA1—gonad—testicular cancer	0.00298	0.0343	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—testicular cancer	0.00274	0.00461	CbGbCtD
Bortezomib—PSMB5—seminal vesicle—testicular cancer	0.00269	0.031	CbGeAlD
Bortezomib—PSMB1—embryo—testicular cancer	0.0025	0.0288	CbGeAlD
Bortezomib—PSMB2—embryo—testicular cancer	0.00244	0.0281	CbGeAlD
Bortezomib—PSMA1—female gonad—testicular cancer	0.00242	0.0279	CbGeAlD
Bortezomib—PSMB1—seminal vesicle—testicular cancer	0.00235	0.0271	CbGeAlD
Bortezomib—PSMB2—seminal vesicle—testicular cancer	0.00229	0.0264	CbGeAlD
Bortezomib—CTSG—testis—testicular cancer	0.00223	0.0257	CbGeAlD
Bortezomib—PSMD2—gonad—testicular cancer	0.00221	0.0255	CbGeAlD
Bortezomib—PSMA1—testis—testicular cancer	0.00214	0.0247	CbGeAlD
Bortezomib—PSMD1—female gonad—testicular cancer	0.00203	0.0234	CbGeAlD
Bortezomib—SLC31A1—seminal vesicle—testicular cancer	0.00199	0.0229	CbGeAlD
Bortezomib—PSMD1—testis—testicular cancer	0.0018	0.0207	CbGeAlD
Bortezomib—PSMD2—female gonad—testicular cancer	0.0018	0.0207	CbGeAlD
Bortezomib—PSMB8—female gonad—testicular cancer	0.00179	0.0206	CbGeAlD
Bortezomib—PSMB1—gonad—testicular cancer	0.0017	0.0196	CbGeAlD
Bortezomib—PSMB2—gonad—testicular cancer	0.00166	0.0191	CbGeAlD
Bortezomib—CTSG—lymph node—testicular cancer	0.00162	0.0187	CbGeAlD
Bortezomib—PSMD2—testis—testicular cancer	0.0016	0.0184	CbGeAlD
Bortezomib—PSMB8—testis—testicular cancer	0.00159	0.0183	CbGeAlD
Bortezomib—PSMB5—female gonad—testicular cancer	0.00158	0.0182	CbGeAlD
Bortezomib—PSMA1—lymph node—testicular cancer	0.00155	0.0179	CbGeAlD
Bortezomib—SLC31A1—gonad—testicular cancer	0.00144	0.0165	CbGeAlD
Bortezomib—PSMB5—testis—testicular cancer	0.0014	0.0161	CbGeAlD
Bortezomib—PSMB1—female gonad—testicular cancer	0.00138	0.0159	CbGeAlD
Bortezomib—PSMB2—female gonad—testicular cancer	0.00135	0.0155	CbGeAlD
Bortezomib—PSMD1—lymph node—testicular cancer	0.00131	0.015	CbGeAlD
Bortezomib—PSMB1—testis—testicular cancer	0.00122	0.0141	CbGeAlD
Bortezomib—PSMB2—testis—testicular cancer	0.00119	0.0138	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—testicular cancer	0.00118	0.35	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—testicular cancer	0.00118	0.35	CbGdCrCtD
Bortezomib—SLC31A1—female gonad—testicular cancer	0.00117	0.0134	CbGeAlD
Bortezomib—PSMD2—lymph node—testicular cancer	0.00116	0.0133	CbGeAlD
Bortezomib—PSMB8—lymph node—testicular cancer	0.00115	0.0132	CbGeAlD
Bortezomib—SLC31A1—testis—testicular cancer	0.00103	0.0119	CbGeAlD
Bortezomib—PSMB5—lymph node—testicular cancer	0.00102	0.0117	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinblastine—testicular cancer	0.00101	0.3	CbGdCrCtD
Bortezomib—PSMB1—lymph node—testicular cancer	0.000887	0.0102	CbGeAlD
Bortezomib—PSMB2—lymph node—testicular cancer	0.000866	0.00997	CbGeAlD
Bortezomib—SLC31A1—lymph node—testicular cancer	0.00075	0.00864	CbGeAlD
Bortezomib—PTGS1—seminal vesicle—testicular cancer	0.000593	0.00683	CbGeAlD
Bortezomib—CYP1A1—female gonad—testicular cancer	0.000396	0.00456	CbGeAlD
Bortezomib—CYP2C8—testis—testicular cancer	0.000381	0.00438	CbGeAlD
Bortezomib—PTGS1—female gonad—testicular cancer	0.000348	0.00401	CbGeAlD
Bortezomib—PTGS1—testis—testicular cancer	0.000309	0.00356	CbGeAlD
Bortezomib—CYP2D6—female gonad—testicular cancer	0.000286	0.00329	CbGeAlD
Bortezomib—CYP1A1—lymph node—testicular cancer	0.000255	0.00293	CbGeAlD
Bortezomib—CYP2D6—testis—testicular cancer	0.000254	0.00292	CbGeAlD
Bortezomib—PTGS1—lymph node—testicular cancer	0.000224	0.00258	CbGeAlD
Bortezomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000214	0.00248	CbGpPWpGaD
Bortezomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000214	0.00248	CbGpPWpGaD
Bortezomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000214	0.00248	CbGpPWpGaD
Bortezomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000211	0.00245	CbGpPWpGaD
Bortezomib—PSMA1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.00021	0.00243	CbGpPWpGaD
Bortezomib—PSMD1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000209	0.00242	CbGpPWpGaD
Bortezomib—PSMD2—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000208	0.00241	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—MAD1L1—testicular cancer	0.000201	0.00233	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—MAD1L1—testicular cancer	0.0002	0.00232	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—KIT—testicular cancer	0.0002	0.00232	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—MAD1L1—testicular cancer	0.000199	0.00231	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—KIT—testicular cancer	0.000199	0.00231	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000199	0.0023	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000199	0.0023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000199	0.0023	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—KIT—testicular cancer	0.000198	0.0023	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—BCL10—testicular cancer	0.000196	0.00227	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000196	0.00227	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—BCL10—testicular cancer	0.000195	0.00226	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—BCL10—testicular cancer	0.000194	0.00225	CbGpPWpGaD
Bortezomib—PTGS1—Biological oxidations—HPGDS—testicular cancer	0.000191	0.00222	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000187	0.00217	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000187	0.00217	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000187	0.00217	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000184	0.00214	CbGpPWpGaD
Bortezomib—PSMB2—M Phase—H2AFZ—testicular cancer	0.000174	0.00201	CbGpPWpGaD
Bortezomib—PSMB1—M Phase—H2AFZ—testicular cancer	0.000174	0.00201	CbGpPWpGaD
Bortezomib—PSMB5—M Phase—H2AFZ—testicular cancer	0.000174	0.00201	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000172	0.00199	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000172	0.00199	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000172	0.00199	CbGpPWpGaD
Bortezomib—PSMB8—M Phase—H2AFZ—testicular cancer	0.000171	0.00198	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000171	0.00198	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000171	0.00198	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000171	0.00198	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000169	0.00196	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—MAD1L1—testicular cancer	0.000168	0.00195	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—DNMT3L—testicular cancer	0.000168	0.00195	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—DNMT3L—testicular cancer	0.000168	0.00195	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—DNMT3L—testicular cancer	0.000168	0.00195	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—DNMT3L—testicular cancer	0.000166	0.00192	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—FGFR3—testicular cancer	0.000165	0.00192	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—FGFR3—testicular cancer	0.000165	0.00192	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—FGFR3—testicular cancer	0.000165	0.00192	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by Wnt—H2AFZ—testicular cancer	0.000164	0.0019	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by Wnt—H2AFZ—testicular cancer	0.000164	0.0019	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by Wnt—H2AFZ—testicular cancer	0.000164	0.0019	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—FGFR3—testicular cancer	0.000163	0.00189	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by Wnt—H2AFZ—testicular cancer	0.000162	0.00187	CbGpPWpGaD
Bortezomib—PSMB1—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000159	0.00184	CbGpPWpGaD
Bortezomib—PSMB2—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000159	0.00184	CbGpPWpGaD
Bortezomib—PSMB5—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000159	0.00184	CbGpPWpGaD
Bortezomib—CTSG—Metabolism of proteins—MMP2—testicular cancer	0.000158	0.00183	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—INSL3—testicular cancer	0.000158	0.00183	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000157	0.00182	CbGpPWpGaD
Bortezomib—PSMB8—Mitotic M-M/G1 phases—H2AFZ—testicular cancer	0.000157	0.00182	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—INSL3—testicular cancer	0.000157	0.00182	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000156	0.00181	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—INSL3—testicular cancer	0.000156	0.00181	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000155	0.0018	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—MAD1L1—testicular cancer	0.000153	0.00177	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—MAD1L1—testicular cancer	0.000153	0.00177	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—MAD1L1—testicular cancer	0.000153	0.00177	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—KIT—testicular cancer	0.000152	0.00176	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—KIT—testicular cancer	0.000152	0.00176	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—KIT—testicular cancer	0.000152	0.00176	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—MAD1L1—testicular cancer	0.00015	0.00174	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—KIT—testicular cancer	0.00015	0.00173	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—BCL10—testicular cancer	0.000149	0.00172	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—BCL10—testicular cancer	0.000149	0.00172	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—BCL10—testicular cancer	0.000149	0.00172	CbGpPWpGaD
Bortezomib—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000147	0.0017	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—BCL10—testicular cancer	0.000147	0.0017	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—H2AFZ—testicular cancer	0.00014	0.00163	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—H2AFZ—testicular cancer	0.00014	0.00162	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—H2AFZ—testicular cancer	0.000139	0.00161	CbGpPWpGaD
Bortezomib—CYP1A1—Biological oxidations—HPGDS—testicular cancer	0.000135	0.00156	CbGpPWpGaD
Bortezomib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000123	0.00143	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—INSL3—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—INSL3—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—INSL3—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—BCL10—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000119	0.00138	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—BCL10—testicular cancer	0.000118	0.00137	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—KITLG—testicular cancer	0.000118	0.00137	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—BCL10—testicular cancer	0.000118	0.00137	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KITLG—testicular cancer	0.000118	0.00136	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—INSL3—testicular cancer	0.000118	0.00136	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—H2AFZ—testicular cancer	0.000117	0.00136	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KITLG—testicular cancer	0.000117	0.00136	CbGpPWpGaD
Bortezomib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	0.00011	0.00128	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—H2AFZ—testicular cancer	0.000106	0.00123	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—H2AFZ—testicular cancer	0.000106	0.00123	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—H2AFZ—testicular cancer	0.000106	0.00123	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—H2AFZ—testicular cancer	0.000105	0.00122	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000101	0.00117	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000101	0.00116	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—BCL10—testicular cancer	9.02e-05	0.00105	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—BCL10—testicular cancer	9.02e-05	0.00105	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—BCL10—testicular cancer	9.02e-05	0.00105	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KITLG—testicular cancer	8.97e-05	0.00104	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KITLG—testicular cancer	8.97e-05	0.00104	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KITLG—testicular cancer	8.97e-05	0.00104	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—BCL10—testicular cancer	8.89e-05	0.00103	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KITLG—testicular cancer	8.84e-05	0.00102	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—FGFR3—testicular cancer	8.79e-05	0.00102	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—FGFR3—testicular cancer	8.75e-05	0.00101	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—FGFR3—testicular cancer	8.71e-05	0.00101	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	8.59e-05	0.000995	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—HPGDS—testicular cancer	8.25e-05	0.000956	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—HPGDS—testicular cancer	8.21e-05	0.000952	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—HPGDS—testicular cancer	8.17e-05	0.000947	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—KIT—testicular cancer	8.07e-05	0.000935	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KIT—testicular cancer	8.03e-05	0.000931	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KIT—testicular cancer	8e-05	0.000927	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—H2AFZ—testicular cancer	7.76e-05	0.000899	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—H2AFZ—testicular cancer	7.72e-05	0.000894	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—H2AFZ—testicular cancer	7.68e-05	0.00089	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.34e-05	0.000851	CbGpPWpGaD
Bortezomib—PSMA1—Disease—H2AFZ—testicular cancer	7.2e-05	0.000834	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KITLG—testicular cancer	7.18e-05	0.000831	CbGpPWpGaD
Bortezomib—PSMD1—Disease—H2AFZ—testicular cancer	7.17e-05	0.00083	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KITLG—testicular cancer	7.14e-05	0.000828	CbGpPWpGaD
Bortezomib—PSMD2—Disease—H2AFZ—testicular cancer	7.13e-05	0.000827	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KITLG—testicular cancer	7.11e-05	0.000824	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—FGFR3—testicular cancer	6.66e-05	0.000772	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—FGFR3—testicular cancer	6.66e-05	0.000772	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—FGFR3—testicular cancer	6.66e-05	0.000772	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	6.63e-05	0.000768	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KITLG—testicular cancer	6.62e-05	0.000768	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KITLG—testicular cancer	6.59e-05	0.000764	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—FGFR3—testicular cancer	6.57e-05	0.000761	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KITLG—testicular cancer	6.56e-05	0.00076	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—HPGDS—testicular cancer	6.25e-05	0.000725	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—HPGDS—testicular cancer	6.25e-05	0.000725	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—HPGDS—testicular cancer	6.25e-05	0.000725	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—HPGDS—testicular cancer	6.17e-05	0.000715	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KIT—testicular cancer	6.12e-05	0.000709	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KIT—testicular cancer	6.12e-05	0.000709	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KIT—testicular cancer	6.12e-05	0.000709	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KIT—testicular cancer	6.03e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—STK11—testicular cancer	6e-05	0.000695	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—STK11—testicular cancer	5.97e-05	0.000692	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—STK11—testicular cancer	5.94e-05	0.000688	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—H2AFZ—testicular cancer	5.88e-05	0.000681	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—H2AFZ—testicular cancer	5.88e-05	0.000681	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—H2AFZ—testicular cancer	5.88e-05	0.000681	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—H2AFZ—testicular cancer	5.79e-05	0.000672	CbGpPWpGaD
Bortezomib—PSMB5—Disease—H2AFZ—testicular cancer	5.46e-05	0.000632	CbGpPWpGaD
Bortezomib—PSMB1—Disease—H2AFZ—testicular cancer	5.46e-05	0.000632	CbGpPWpGaD
Bortezomib—PSMB2—Disease—H2AFZ—testicular cancer	5.46e-05	0.000632	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KITLG—testicular cancer	5.44e-05	0.00063	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KITLG—testicular cancer	5.44e-05	0.00063	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KITLG—testicular cancer	5.44e-05	0.00063	CbGpPWpGaD
Bortezomib—PSMB8—Disease—H2AFZ—testicular cancer	5.38e-05	0.000624	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KITLG—testicular cancer	5.36e-05	0.000621	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—FGFR3—testicular cancer	5.33e-05	0.000618	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—FGFR3—testicular cancer	5.31e-05	0.000615	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—FGFR3—testicular cancer	5.28e-05	0.000612	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.17e-05	0.000599	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—H2AFZ—testicular cancer	5.04e-05	0.000584	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KITLG—testicular cancer	5.02e-05	0.000582	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KITLG—testicular cancer	5.02e-05	0.000582	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KITLG—testicular cancer	5.02e-05	0.000582	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—H2AFZ—testicular cancer	5.02e-05	0.000582	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—STK11—testicular cancer	5.01e-05	0.000581	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—H2AFZ—testicular cancer	4.99e-05	0.000579	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—STK11—testicular cancer	4.99e-05	0.000578	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—STK11—testicular cancer	4.97e-05	0.000576	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KITLG—testicular cancer	4.95e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMA1—Disease—FGFR3—testicular cancer	4.92e-05	0.000571	CbGpPWpGaD
Bortezomib—PSMD1—Disease—FGFR3—testicular cancer	4.9e-05	0.000568	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KIT—testicular cancer	4.9e-05	0.000567	CbGpPWpGaD
Bortezomib—PSMD2—Disease—FGFR3—testicular cancer	4.88e-05	0.000565	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KIT—testicular cancer	4.87e-05	0.000565	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KIT—testicular cancer	4.85e-05	0.000562	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.74e-05	0.00055	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KITLG—testicular cancer	4.64e-05	0.000538	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KITLG—testicular cancer	4.62e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KITLG—testicular cancer	4.59e-05	0.000532	CbGpPWpGaD
Bortezomib—Urticaria—Etoposide—testicular cancer	4.55e-05	0.000198	CcSEcCtD
Bortezomib—PSMB1—Metabolism—STK11—testicular cancer	4.54e-05	0.000527	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—STK11—testicular cancer	4.54e-05	0.000527	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—STK11—testicular cancer	4.54e-05	0.000527	CbGpPWpGaD
Bortezomib—Haemoglobin—Epirubicin—testicular cancer	4.54e-05	0.000198	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—testicular cancer	4.54e-05	0.000198	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—PSMA1—Disease—KIT—testicular cancer	4.52e-05	0.000524	CbGpPWpGaD
Bortezomib—Haemorrhage—Epirubicin—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—testicular cancer	4.52e-05	0.000197	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—testicular cancer	4.51e-05	0.000197	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—testicular cancer	4.5e-05	0.000196	CcSEcCtD
Bortezomib—PSMD1—Disease—KIT—testicular cancer	4.5e-05	0.000521	CbGpPWpGaD
Bortezomib—Hypoaesthesia—Epirubicin—testicular cancer	4.49e-05	0.000196	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—testicular cancer	4.48e-05	0.000195	CcSEcCtD
Bortezomib—PSMB8—Metabolism—STK11—testicular cancer	4.48e-05	0.000519	CbGpPWpGaD
Bortezomib—Cardiac disorder—Methotrexate—testicular cancer	4.48e-05	0.000195	CcSEcCtD
Bortezomib—PSMD2—Disease—KIT—testicular cancer	4.48e-05	0.000519	CbGpPWpGaD
Bortezomib—Urinary tract disorder—Epirubicin—testicular cancer	4.46e-05	0.000195	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—testicular cancer	4.45e-05	0.000194	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—testicular cancer	4.44e-05	0.000194	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—testicular cancer	4.44e-05	0.000194	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—testicular cancer	4.43e-05	0.000193	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—testicular cancer	4.4e-05	0.000192	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—testicular cancer	4.39e-05	0.000191	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—testicular cancer	4.38e-05	0.000191	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—testicular cancer	4.37e-05	0.00019	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—testicular cancer	4.36e-05	0.00019	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—testicular cancer	4.35e-05	0.00019	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—testicular cancer	4.35e-05	0.00019	CcSEcCtD
Bortezomib—Chills—Methotrexate—testicular cancer	4.33e-05	0.000189	CcSEcCtD
Bortezomib—Nausea—Ifosfamide—testicular cancer	4.3e-05	0.000188	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—testicular cancer	4.27e-05	0.000186	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—testicular cancer	4.27e-05	0.000186	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—testicular cancer	4.25e-05	0.000186	CcSEcCtD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.23e-05	0.000491	CbGpPWpGaD
Bortezomib—Mental disorder—Methotrexate—testicular cancer	4.23e-05	0.000184	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—testicular cancer	4.22e-05	0.000184	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—testicular cancer	4.22e-05	0.000184	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—testicular cancer	4.21e-05	0.000184	CcSEcCtD
Bortezomib—Erythema—Methotrexate—testicular cancer	4.2e-05	0.000183	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—testicular cancer	4.2e-05	0.000183	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—testicular cancer	4.2e-05	0.000183	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—testicular cancer	4.19e-05	0.000183	CcSEcCtD
Bortezomib—Flushing—Epirubicin—testicular cancer	4.19e-05	0.000183	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—testicular cancer	4.18e-05	0.000182	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—testicular cancer	4.18e-05	0.000182	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—testicular cancer	4.16e-05	0.000181	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—testicular cancer	4.13e-05	0.00018	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—testicular cancer	4.12e-05	0.00018	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—testicular cancer	4.11e-05	0.000179	CcSEcCtD
Bortezomib—Asthenia—Etoposide—testicular cancer	4.11e-05	0.000179	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—testicular cancer	4.11e-05	0.000179	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—testicular cancer	4.1e-05	0.000179	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—testicular cancer	4.1e-05	0.000179	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—testicular cancer	4.08e-05	0.000178	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—testicular cancer	4.07e-05	0.000178	CcSEcCtD
Bortezomib—Back pain—Methotrexate—testicular cancer	4.06e-05	0.000177	CcSEcCtD
Bortezomib—Chills—Epirubicin—testicular cancer	4.05e-05	0.000177	CcSEcCtD
Bortezomib—Pruritus—Etoposide—testicular cancer	4.05e-05	0.000177	CcSEcCtD
Bortezomib—PSMB2—Immune System—FGFR3—testicular cancer	4.04e-05	0.000468	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—FGFR3—testicular cancer	4.04e-05	0.000468	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—FGFR3—testicular cancer	4.04e-05	0.000468	CbGpPWpGaD
Bortezomib—Arrhythmia—Epirubicin—testicular cancer	4.03e-05	0.000176	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—testicular cancer	4.03e-05	0.000176	CcSEcCtD
Bortezomib—PSMB8—Immune System—FGFR3—testicular cancer	3.98e-05	0.000462	CbGpPWpGaD
Bortezomib—Vomiting—Cisplatin—testicular cancer	3.97e-05	0.000173	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—testicular cancer	3.96e-05	0.000173	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—testicular cancer	3.96e-05	0.000173	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—testicular cancer	3.95e-05	0.000172	CcSEcCtD
Bortezomib—Rash—Cisplatin—testicular cancer	3.94e-05	0.000172	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—testicular cancer	3.94e-05	0.000172	CcSEcCtD
Bortezomib—Erythema—Epirubicin—testicular cancer	3.93e-05	0.000171	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—testicular cancer	3.93e-05	0.000171	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—testicular cancer	3.92e-05	0.000171	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—testicular cancer	3.9e-05	0.00017	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—testicular cancer	3.9e-05	0.00017	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—testicular cancer	3.9e-05	0.00017	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—testicular cancer	3.88e-05	0.000169	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—testicular cancer	3.88e-05	0.000169	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—testicular cancer	3.88e-05	0.000169	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—testicular cancer	3.87e-05	0.000169	CcSEcCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.86e-05	0.000447	CbGpPWpGaD
Bortezomib—Dysgeusia—Epirubicin—testicular cancer	3.85e-05	0.000168	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—H2AFZ—testicular cancer	3.82e-05	0.000443	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—H2AFZ—testicular cancer	3.82e-05	0.000443	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—H2AFZ—testicular cancer	3.82e-05	0.000443	CbGpPWpGaD
Bortezomib—Back pain—Epirubicin—testicular cancer	3.8e-05	0.000166	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—STK11—testicular cancer	3.8e-05	0.00044	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STK11—testicular cancer	3.8e-05	0.00044	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STK11—testicular cancer	3.8e-05	0.00044	CbGpPWpGaD
Bortezomib—Angiopathy—Doxorubicin—testicular cancer	3.79e-05	0.000165	CcSEcCtD
Bortezomib—Malaise—Methotrexate—testicular cancer	3.79e-05	0.000165	CcSEcCtD
Bortezomib—Dizziness—Etoposide—testicular cancer	3.78e-05	0.000165	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—testicular cancer	3.78e-05	0.000165	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—testicular cancer	3.77e-05	0.000165	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—testicular cancer	3.77e-05	0.000165	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—H2AFZ—testicular cancer	3.77e-05	0.000437	CbGpPWpGaD
Bortezomib—Mediastinal disorder—Doxorubicin—testicular cancer	3.77e-05	0.000164	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—testicular cancer	3.76e-05	0.000164	CcSEcCtD
Bortezomib—Chills—Doxorubicin—testicular cancer	3.75e-05	0.000164	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—STK11—testicular cancer	3.75e-05	0.000434	CbGpPWpGaD
Bortezomib—Arrhythmia—Doxorubicin—testicular cancer	3.73e-05	0.000163	CcSEcCtD
Bortezomib—PSMB5—Disease—FGFR3—testicular cancer	3.73e-05	0.000432	CbGpPWpGaD
Bortezomib—PSMB2—Disease—FGFR3—testicular cancer	3.73e-05	0.000432	CbGpPWpGaD
Bortezomib—PSMB1—Disease—FGFR3—testicular cancer	3.73e-05	0.000432	CbGpPWpGaD
Bortezomib—Nausea—Cisplatin—testicular cancer	3.71e-05	0.000162	CcSEcCtD
Bortezomib—PSMB5—Immune System—KIT—testicular cancer	3.71e-05	0.00043	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KIT—testicular cancer	3.71e-05	0.00043	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KIT—testicular cancer	3.71e-05	0.00043	CbGpPWpGaD
Bortezomib—Vision blurred—Epirubicin—testicular cancer	3.7e-05	0.000162	CcSEcCtD
Bortezomib—PSMB8—Disease—FGFR3—testicular cancer	3.68e-05	0.000426	CbGpPWpGaD
Bortezomib—Cough—Methotrexate—testicular cancer	3.67e-05	0.00016	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—testicular cancer	3.66e-05	0.00016	CcSEcCtD
Bortezomib—PSMB8—Immune System—KIT—testicular cancer	3.66e-05	0.000424	CbGpPWpGaD
Bortezomib—Ill-defined disorder—Epirubicin—testicular cancer	3.65e-05	0.000159	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—testicular cancer	3.64e-05	0.000159	CcSEcCtD
Bortezomib—Vomiting—Etoposide—testicular cancer	3.64e-05	0.000159	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—testicular cancer	3.64e-05	0.000159	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—testicular cancer	3.64e-05	0.000159	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—testicular cancer	3.63e-05	0.000158	CcSEcCtD
Bortezomib—Agitation—Epirubicin—testicular cancer	3.61e-05	0.000158	CcSEcCtD
Bortezomib—Rash—Etoposide—testicular cancer	3.61e-05	0.000157	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—testicular cancer	3.61e-05	0.000157	CcSEcCtD
Bortezomib—Headache—Etoposide—testicular cancer	3.59e-05	0.000156	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—testicular cancer	3.58e-05	0.000156	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—testicular cancer	3.58e-05	0.000156	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—testicular cancer	3.58e-05	0.000156	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—testicular cancer	3.58e-05	0.000156	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—testicular cancer	3.56e-05	0.000155	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.55e-05	0.000155	CcSEcCtD
Bortezomib—Malaise—Epirubicin—testicular cancer	3.54e-05	0.000155	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—testicular cancer	3.53e-05	0.000154	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—testicular cancer	3.53e-05	0.000154	CcSEcCtD
Bortezomib—Syncope—Epirubicin—testicular cancer	3.53e-05	0.000154	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—testicular cancer	3.52e-05	0.000153	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—testicular cancer	3.52e-05	0.000153	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—KITLG—testicular cancer	3.52e-05	0.000407	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KITLG—testicular cancer	3.52e-05	0.000407	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KITLG—testicular cancer	3.52e-05	0.000407	CbGpPWpGaD
Bortezomib—Muscle spasms—Doxorubicin—testicular cancer	3.5e-05	0.000153	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—testicular cancer	3.47e-05	0.000152	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—KITLG—testicular cancer	3.47e-05	0.000402	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—testicular cancer	3.46e-05	0.000151	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—testicular cancer	3.46e-05	0.000151	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—FGFR3—testicular cancer	3.45e-05	0.0004	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FGFR3—testicular cancer	3.43e-05	0.000398	CbGpPWpGaD
Bortezomib—Cough—Epirubicin—testicular cancer	3.43e-05	0.00015	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—testicular cancer	3.43e-05	0.00015	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—testicular cancer	3.43e-05	0.00015	CcSEcCtD
Bortezomib—PSMB1—Disease—KIT—testicular cancer	3.43e-05	0.000397	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KIT—testicular cancer	3.43e-05	0.000397	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KIT—testicular cancer	3.43e-05	0.000397	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FGFR3—testicular cancer	3.42e-05	0.000396	CbGpPWpGaD
Bortezomib—Convulsion—Epirubicin—testicular cancer	3.41e-05	0.000149	CcSEcCtD
Bortezomib—Infection—Methotrexate—testicular cancer	3.41e-05	0.000149	CcSEcCtD
Bortezomib—Nausea—Etoposide—testicular cancer	3.4e-05	0.000148	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—testicular cancer	3.39e-05	0.000148	CcSEcCtD
Bortezomib—PSMB8—Disease—KIT—testicular cancer	3.38e-05	0.000391	CbGpPWpGaD
Bortezomib—Ill-defined disorder—Doxorubicin—testicular cancer	3.37e-05	0.000147	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—testicular cancer	3.36e-05	0.000147	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—testicular cancer	3.36e-05	0.000147	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—testicular cancer	3.36e-05	0.000146	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—testicular cancer	3.35e-05	0.000146	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—testicular cancer	3.35e-05	0.000146	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—testicular cancer	3.35e-05	0.000146	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—testicular cancer	3.34e-05	0.000146	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—testicular cancer	3.34e-05	0.000145	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—testicular cancer	3.33e-05	0.000145	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.32e-05	0.000145	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—testicular cancer	3.31e-05	0.000145	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—testicular cancer	3.31e-05	0.000144	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.3e-05	0.000382	CbGpPWpGaD
Bortezomib—Malaise—Doxorubicin—testicular cancer	3.28e-05	0.000143	CcSEcCtD
Bortezomib—PTGS1—Metabolism—HPGDS—testicular cancer	3.27e-05	0.000379	CbGpPWpGaD
Bortezomib—Vertigo—Doxorubicin—testicular cancer	3.27e-05	0.000143	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—testicular cancer	3.27e-05	0.000143	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—testicular cancer	3.26e-05	0.000142	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—testicular cancer	3.26e-05	0.000142	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—testicular cancer	3.23e-05	0.000141	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—testicular cancer	3.21e-05	0.00014	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—testicular cancer	3.21e-05	0.00014	CcSEcCtD
Bortezomib—Oedema—Epirubicin—testicular cancer	3.21e-05	0.00014	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—testicular cancer	3.2e-05	0.00014	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—testicular cancer	3.2e-05	0.000139	CcSEcCtD
Bortezomib—Infection—Epirubicin—testicular cancer	3.19e-05	0.000139	CcSEcCtD
Bortezomib—Cough—Doxorubicin—testicular cancer	3.17e-05	0.000138	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—KIT—testicular cancer	3.17e-05	0.000367	CbGpPWpGaD
Bortezomib—Shock—Epirubicin—testicular cancer	3.16e-05	0.000138	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—testicular cancer	3.15e-05	0.000137	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—KIT—testicular cancer	3.15e-05	0.000365	CbGpPWpGaD
Bortezomib—Nervous system disorder—Epirubicin—testicular cancer	3.15e-05	0.000137	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—testicular cancer	3.14e-05	0.000137	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—testicular cancer	3.14e-05	0.000137	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—KIT—testicular cancer	3.14e-05	0.000363	CbGpPWpGaD
Bortezomib—Tachycardia—Epirubicin—testicular cancer	3.13e-05	0.000137	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.12e-05	0.000136	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—testicular cancer	3.12e-05	0.000136	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—testicular cancer	3.1e-05	0.000135	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—testicular cancer	3.1e-05	0.000135	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—testicular cancer	3.1e-05	0.000135	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—testicular cancer	3.1e-05	0.000135	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—testicular cancer	3.1e-05	0.000135	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—testicular cancer	3.09e-05	0.000135	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—testicular cancer	3.08e-05	0.000134	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.08e-05	0.000134	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—testicular cancer	3.06e-05	0.000133	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—testicular cancer	3.06e-05	0.000133	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—testicular cancer	3.06e-05	0.000133	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—testicular cancer	3.02e-05	0.000132	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—testicular cancer	3e-05	0.000131	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—testicular cancer	2.99e-05	0.000131	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—testicular cancer	2.98e-05	0.00013	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—testicular cancer	2.97e-05	0.000129	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—testicular cancer	2.97e-05	0.000129	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—testicular cancer	2.96e-05	0.000129	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—testicular cancer	2.96e-05	0.000129	CcSEcCtD
Bortezomib—Infection—Doxorubicin—testicular cancer	2.95e-05	0.000129	CcSEcCtD
Bortezomib—Pain—Methotrexate—testicular cancer	2.93e-05	0.000128	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.92e-05	0.000127	CcSEcCtD
Bortezomib—Shock—Doxorubicin—testicular cancer	2.92e-05	0.000127	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—testicular cancer	2.91e-05	0.000127	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—testicular cancer	2.91e-05	0.000127	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—testicular cancer	2.9e-05	0.000127	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—testicular cancer	2.9e-05	0.000126	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—testicular cancer	2.88e-05	0.000126	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—testicular cancer	2.88e-05	0.000126	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—testicular cancer	2.87e-05	0.000125	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—testicular cancer	2.86e-05	0.000125	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—testicular cancer	2.83e-05	0.000123	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—testicular cancer	2.83e-05	0.000123	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—testicular cancer	2.82e-05	0.000123	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—testicular cancer	2.8e-05	0.000122	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—testicular cancer	2.79e-05	0.000122	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—testicular cancer	2.77e-05	0.000121	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.77e-05	0.000121	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—testicular cancer	2.77e-05	0.000121	CcSEcCtD
Bortezomib—Constipation—Epirubicin—testicular cancer	2.74e-05	0.00012	CcSEcCtD
Bortezomib—Pain—Epirubicin—testicular cancer	2.74e-05	0.00012	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—testicular cancer	2.72e-05	0.000119	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—testicular cancer	2.71e-05	0.000118	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—testicular cancer	2.71e-05	0.000118	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.7e-05	0.000118	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—testicular cancer	2.68e-05	0.000117	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—testicular cancer	2.67e-05	0.000116	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—testicular cancer	2.65e-05	0.000115	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—testicular cancer	2.64e-05	0.000115	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—testicular cancer	2.62e-05	0.000114	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—testicular cancer	2.61e-05	0.000114	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—FGFR3—testicular cancer	2.61e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FGFR3—testicular cancer	2.61e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FGFR3—testicular cancer	2.61e-05	0.000303	CbGpPWpGaD
Bortezomib—Decreased appetite—Doxorubicin—testicular cancer	2.58e-05	0.000113	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—FGFR3—testicular cancer	2.58e-05	0.000299	CbGpPWpGaD
Bortezomib—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.56e-05	0.000112	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—testicular cancer	2.56e-05	0.000112	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—testicular cancer	2.55e-05	0.000111	CcSEcCtD
Bortezomib—Pain—Doxorubicin—testicular cancer	2.54e-05	0.000111	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—testicular cancer	2.54e-05	0.000111	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—testicular cancer	2.54e-05	0.000111	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—testicular cancer	2.54e-05	0.000111	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—testicular cancer	2.53e-05	0.00011	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—testicular cancer	2.46e-05	0.000107	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—testicular cancer	2.45e-05	0.000107	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—testicular cancer	2.43e-05	0.000106	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—testicular cancer	2.43e-05	0.000106	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—KIT—testicular cancer	2.4e-05	0.000278	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KIT—testicular cancer	2.4e-05	0.000278	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KIT—testicular cancer	2.4e-05	0.000278	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—STK11—testicular cancer	2.38e-05	0.000275	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KIT—testicular cancer	2.37e-05	0.000274	CbGpPWpGaD
Bortezomib—Hypersensitivity—Epirubicin—testicular cancer	2.36e-05	0.000103	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—testicular cancer	2.36e-05	0.000103	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—testicular cancer	2.35e-05	0.000102	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—testicular cancer	2.35e-05	0.000102	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—testicular cancer	2.35e-05	0.000102	CcSEcCtD
Bortezomib—CYP1A1—Metabolism—HPGDS—testicular cancer	2.3e-05	0.000267	CbGpPWpGaD
Bortezomib—Asthenia—Epirubicin—testicular cancer	2.3e-05	0.0001	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—testicular cancer	2.27e-05	9.9e-05	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—testicular cancer	2.27e-05	9.89e-05	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—testicular cancer	2.2e-05	9.57e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—testicular cancer	2.19e-05	9.54e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—testicular cancer	2.18e-05	9.51e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—testicular cancer	2.16e-05	9.43e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—testicular cancer	2.16e-05	9.42e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—testicular cancer	2.15e-05	9.37e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—testicular cancer	2.13e-05	9.29e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—testicular cancer	2.12e-05	9.25e-05	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—HPGDS—testicular cancer	2.11e-05	0.000245	CbGpPWpGaD
Bortezomib—Pruritus—Doxorubicin—testicular cancer	2.1e-05	9.16e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—testicular cancer	2.04e-05	8.9e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—testicular cancer	2.04e-05	8.88e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—testicular cancer	2.03e-05	8.86e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—testicular cancer	2.02e-05	8.82e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—testicular cancer	2.02e-05	8.81e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—testicular cancer	2.01e-05	8.77e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—testicular cancer	1.96e-05	8.56e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—testicular cancer	1.91e-05	8.31e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—testicular cancer	1.89e-05	8.23e-05	CcSEcCtD
Bortezomib—CYP2C19—Metabolism—HPGDS—testicular cancer	1.89e-05	0.000218	CbGpPWpGaD
Bortezomib—Rash—Doxorubicin—testicular cancer	1.87e-05	8.16e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—testicular cancer	1.87e-05	8.16e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—testicular cancer	1.86e-05	8.11e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—testicular cancer	1.76e-05	7.69e-05	CcSEcCtD
Bortezomib—CYP2D6—Metabolism—HPGDS—testicular cancer	1.73e-05	0.000201	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HPGDS—testicular cancer	1.72e-05	0.000199	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—STK11—testicular cancer	1.67e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—STK11—testicular cancer	1.53e-05	0.000178	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HPGDS—testicular cancer	1.47e-05	0.00017	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—STK11—testicular cancer	1.37e-05	0.000159	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—STK11—testicular cancer	1.26e-05	0.000146	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—STK11—testicular cancer	1.25e-05	0.000145	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGDS—testicular cancer	1.13e-05	0.000131	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—STK11—testicular cancer	1.07e-05	0.000124	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STK11—testicular cancer	8.24e-06	9.54e-05	CbGpPWpGaD
